Estrella Immunopharma Stock Cash Flow From Operations
| ESLA Stock | 1.75 0.14 8.70% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Estrella Immunopharma's long-term financial health and intrinsic value.
Estrella | Cash Flow From Operations | Build AI portfolio with Estrella Stock |
Estrella Immunopharma Company Cash Flow From Operations Analysis
Estrella Immunopharma's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Estrella Immunopharma Cash Flow From Operations | (7.64 M) |
Most of Estrella Immunopharma's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Estrella Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Estrella Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Estrella Immunopharma is extremely important. It helps to project a fair market value of Estrella Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Estrella Immunopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Estrella Immunopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Estrella Immunopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Estrella Immunopharma has (7.64 Million) in Cash Flow From Operations. This is 101.45% lower than that of the Biotechnology sector and 112.22% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.79% higher than that of the company.
Estrella Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Estrella Immunopharma's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Estrella Immunopharma could also be used in its relative valuation, which is a method of valuing Estrella Immunopharma by comparing valuation metrics of similar companies.Estrella Immunopharma is currently under evaluation in cash flow from operations category among its peers.
Estrella Fundamentals
| Return On Equity | -2.68 | ||||
| Return On Asset | -1.01 | ||||
| Current Valuation | 27.09 M | ||||
| Shares Outstanding | 37.07 M | ||||
| Shares Owned By Insiders | 70.36 % | ||||
| Shares Owned By Institutions | 1.71 % | ||||
| Number Of Shares Shorted | 26.33 K | ||||
| Price To Book | 241.30 X | ||||
| EBITDA | (8.85 M) | ||||
| Net Income | (8.85 M) | ||||
| Total Debt | 3 M | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (7.64 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (0.24) X | ||||
| Target Price | 16.0 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 64.86 M | ||||
| Total Asset | 3.14 M | ||||
| Retained Earnings | (23.93 M) | ||||
| Working Capital | 4.27 M | ||||
| Net Asset | 3.14 M |
About Estrella Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Estrella Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Estrella Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Estrella Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Estrella Immunopharma is a strong investment it is important to analyze Estrella Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Estrella Immunopharma's future performance. For an informed investment choice regarding Estrella Stock, refer to the following important reports:Check out Estrella Immunopharma Piotroski F Score and Estrella Immunopharma Altman Z Score analysis. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.